<DOC>
	<DOCNO>NCT00002771</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness various combination chemotherapy regimens bone marrow transplantation treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy , Interferon , Bone Marrow Transplantation Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare duration chronic phase chronic myelogenous leukemia ( CML ) survival patient treated standard remission induction comprise hydroxyurea ( HU ) interferon alfa ( IFN-A ) , follow allogeneic bone marrow transplantation consolidation comprise HU IFN-A v cytarabine idarubicin . - Compare frequency hematologic cytogenetic remission ( include elimination Philadelphia-positive and/or BCR/ABL-positive chromosome abnormality ) , time remission , duration remission patient treat regimen . - Correlate quality hematologic cytogenetic remission survival patient treat regimen . - Compare toxic effect regimens patient . - Compare disease progression patient treat regimen . - Correlate duration chronic phase CML survival prognostic criterion significance normal v subnormal leukocyte count patient treat regimen . - Compare survival patient without suitable allogeneic bone marrow donor treat autologous bone marrow transplantation consolidation therapy v consolidation maintenance chemotherapy regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , eligibility allogeneic bone marrow transplantation ( Allo-BMT ) ( yes v ) , donor availability ( sibling vs unrelated v none ) , risk status ( high vs low ) . Induction therapy - Patients receive induction therapy comprise oral hydroxyurea ( HU ) WBC fall 10,000/mm^3 interferon alfa ( IFN-A ) subcutaneously ( SC ) daily begin WBC reduction continue order maintain WBC 2,000-4,000/mm^3 platelet count great 50,000/mm^3 . If WBC 10,000/mm^3 great IFN-A alone , HU must restart . Patients disease progression anti-IFN antibody also receive cytarabine ( ARA-C ) SC 15 day month . Patients develop disease progression receive ARA-C IFN-A take study . - Patients eligible Allo-BMT , sibling donor , age 55 receive induction therapy maximum 1 year proceed regimen B . Patients eligible Allo-BMT , unrelated donor , age 45 receive induction therapy 12-18 month . Those patient cytogenetic remission receive induction therapy 2 year proceed regimen B . Those patient without cytogenetic remission proceed directly regimen B . Patients ineligible Allo-BMT , eligible autologous BMT ( AuBMT ) peripheral blood stem cell transplantation ( PBSCT ) receive induction therapy maximum 1 year proceed regimen C. Patients ineligible Allo-BMT achieve hematologic complete remission ( CR ) within 3 month receive induction therapy 18 month . Those patient cytogenetic remission proceed directly regimen A . Those patient without cytogenetic remission proceed randomization regimen B . Patients ineligible Allo-BMT fail achieve hematologic CR within 9 month proceed randomization regimen B . All patient ineligible Allo-BMT receive induction therapy 1 year . Those patient cytogenetic remission proceed regimen A . Those patient without cytogenetic remission proceed randomization regimen B. Consolidation/maintenance therapy - Patients assign 1 3 regimen . - Regimen A : Patients continue receive IFN-A induction therapy absence disease progression . - Regimen B : Patients receive condition therapy comprise busulfan 4 day and/or total body irradiation , follow Allo-BMT . Patients randomize 1 2 treatment arm . - Arm I : Patients receive consolidation therapy comprise HU IFN-A induction therapy . - Arm II : Patients receive consolidation therapy comprise ARA-C SC every 12 hour day 1-5 idarubicin ( IDA ) IV day 3 4 ( day 5 patient respond disease ) . Consolidation therapy continue every 2 month total 3 course . When blood count recover , patient receive maintenance therapy comprise IFN-A ARA-C ( need ) induction therapy . - Regimen C : Patients receive IDA ARA-C arm II . Patients undergo AuBMT PBSCT . Patients follow every 3-6 month least 4 year . PROJECTED ACCRUAL : Approximately 750 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose chronic myelogenous leukemia chronic phase Philadelphia chromosome bcr/ablpositive Cytogenetic negativity ( analyze separately ) allow least 1 follow criterion meet : Malaise decrease performance status Weight loss 10 % within past 6 month Fever 38.5 C 5 consecutive day Symptomatic splenomegaly Leukocyte count great 50,000/mm^3 Platelet count great 1,000,000/mm^3 PATIENT CHARACTERISTICS : Age : Any age Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : No medical condition would reduce life expectancy No uncontrolled malignancy Not pregnant No contraindication study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon Chemotherapy : No prior cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
</DOC>